Segment Reporting - Summar of Segment Net Loss, Including Significant Segment Expenses (Details) - USD ($) |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Research and development expenses: | ||
| Research expenses | $ 12,628,000 | $ 5,496,000 |
| Personnel-related (including stock-based compensation expense) | 3,709,000 | 2,057,000 |
| Facilities-related and other allocated costs | 230,000 | 202,000 |
| Total Research and development expenses | 16,567,000 | 7,755,000 |
| General and administrative | 5,897,000 | 2,715,000 |
| Interest and dividend income | (889,000) | (1,175,000) |
| Unrealized losses on short-term investments | 13,000 | 15,000 |
| Net loss | $ 21,588,000 | $ 9,310,000 |
| X | ||||||||||
- Definition Facilities-related and other allocated costs No definition available.
|
| X | ||||||||||
- Definition Research expenses No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|